Dianthus Therapeutics (DNTH) Competitors $37.04 -0.12 (-0.32%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$37.05 +0.01 (+0.03%) As of 04:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNTH vs. CRNX, KYMR, RARE, TLX, NAMS, VKTX, XENE, AMRX, SRRK, and IMVTShould you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Crinetics Pharmaceuticals (CRNX), Kymera Therapeutics (KYMR), Ultragenyx Pharmaceutical (RARE), Telix Pharmaceuticals (TLX), NewAmsterdam Pharma (NAMS), Viking Therapeutics (VKTX), Xenon Pharmaceuticals (XENE), AMNEAL PHARMACEUTICALS (AMRX), Scholar Rock (SRRK), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry. Dianthus Therapeutics vs. Its Competitors Crinetics Pharmaceuticals Kymera Therapeutics Ultragenyx Pharmaceutical Telix Pharmaceuticals NewAmsterdam Pharma Viking Therapeutics Xenon Pharmaceuticals AMNEAL PHARMACEUTICALS Scholar Rock Immunovant Dianthus Therapeutics (NASDAQ:DNTH) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership. Do insiders & institutionals hold more shares of DNTH or CRNX? 47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 8.2% of Dianthus Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Crinetics Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts prefer DNTH or CRNX? Dianthus Therapeutics currently has a consensus price target of $61.57, suggesting a potential upside of 66.23%. Crinetics Pharmaceuticals has a consensus price target of $65.33, suggesting a potential upside of 93.47%. Given Crinetics Pharmaceuticals' higher possible upside, analysts clearly believe Crinetics Pharmaceuticals is more favorable than Dianthus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Crinetics Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has better valuation & earnings, DNTH or CRNX? Dianthus Therapeutics has higher revenue and earnings than Crinetics Pharmaceuticals. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDianthus Therapeutics$4.85M245.62-$84.97M-$3.25-11.40Crinetics Pharmaceuticals$1.39M2,284.72-$298.41M-$4.11-8.22 Which has more volatility & risk, DNTH or CRNX? Dianthus Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Is DNTH or CRNX more profitable? Crinetics Pharmaceuticals has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -2,364.56%. Crinetics Pharmaceuticals' return on equity of -32.28% beat Dianthus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dianthus Therapeutics-2,364.56% -34.72% -32.72% Crinetics Pharmaceuticals N/A -32.28%-29.45% Does the media favor DNTH or CRNX? In the previous week, Dianthus Therapeutics had 24 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 32 mentions for Dianthus Therapeutics and 8 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.03 beat Dianthus Therapeutics' score of 0.63 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 11 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryDianthus Therapeutics and Crinetics Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNTH vs. The Competition Export to ExcelMetricDianthus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.20B$3.15B$5.80B$10.16BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-11.4021.2475.1126.39Price / Sales245.62431.67511.76177.24Price / CashN/A44.4425.8129.91Price / Book3.119.6413.456.28Net Income-$84.97M-$53.20M$3.29B$270.38M7 Day Performance4.13%0.07%0.08%1.89%1 Month Performance78.59%4.27%4.59%6.01%1 Year Performance40.20%9.62%75.30%25.26% Dianthus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNTHDianthus Therapeutics2.8784 of 5 stars$37.04-0.3%$61.57+66.2%+27.9%$1.20B$4.85M-11.4080CRNXCrinetics Pharmaceuticals3.7467 of 5 stars$35.14-1.3%$68.86+96.0%-37.2%$3.35B$1.04M-8.55210Positive NewsKYMRKymera Therapeutics2.4853 of 5 stars$43.26-0.6%$58.76+35.8%+2.6%$3.11B$47.07M-12.47170Positive NewsRAREUltragenyx Pharmaceutical4.3844 of 5 stars$31.51-1.0%$81.50+158.6%-50.6%$3.07B$560.23M-5.701,294Positive NewsTLXTelix Pharmaceuticals3.6571 of 5 stars$9.05-0.1%$22.33+146.8%N/A$3.07B$516.72M0.00N/ANAMSNewAmsterdam Pharma3.2123 of 5 stars$25.09-7.1%$41.55+65.6%+51.1%$3.04B$45.56M-15.494Positive NewsHigh Trading VolumeVKTXViking Therapeutics4.1782 of 5 stars$25.48-5.6%$86.92+241.1%-63.9%$3.03BN/A-16.6520XENEXenon Pharmaceuticals2.3986 of 5 stars$38.19-2.6%$53.30+39.6%-11.9%$3.02B$9.43M-10.76210Positive NewsAMRXAMNEAL PHARMACEUTICALS2.6867 of 5 stars$9.73+1.1%$11.60+19.2%+13.6%$3.02B$2.79B973.978,100Positive NewsSRRKScholar Rock4.4735 of 5 stars$31.58+0.5%$45.75+44.9%+292.9%$3.02B$33.19M-10.85140News CoveragePositive NewsAnalyst ForecastGap UpIMVTImmunovant2.4695 of 5 stars$16.37-4.5%$33.60+105.3%-47.7%$2.99BN/A-5.74120Positive News Related Companies and Tools Related Companies Crinetics Pharmaceuticals Alternatives Kymera Therapeutics Alternatives Ultragenyx Pharmaceutical Alternatives Telix Pharmaceuticals Alternatives NewAmsterdam Pharma Alternatives Viking Therapeutics Alternatives Xenon Pharmaceuticals Alternatives AMNEAL PHARMACEUTICALS Alternatives Scholar Rock Alternatives Immunovant Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNTH) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
